Short-course Ocrelizumab ( DrugBank: Ocrelizumab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04767698
(ClinicalTrials.gov)
October 1, 202118/2/2021Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple SclerosisAddition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease ActivityMultiple SclerosisDrug: Belimumab;Drug: Short-course Ocrelizumab;Drug: Continued OcrelizumabJohns Hopkins UniversityGlaxoSmithKlineTerminated18 YearsN/AAll3Phase 2United States